Parad™/Parad+™

Parad™/Parad+™

Accurate Therapies
How can you reduce the use of shock therapy, without prolonging time to arrhythmia termination? With PARAD+, that's how.

  • Inappropriate shocks are linked to anxiety and depression and continue to be a major source of distress to patients5
  • A Fib is the primary cause of inappropriate shocks5 (A Fib prevalence in HF patients: 20-30%4)
  • ATP for fast VT is highly effective and prevents painful shocks3, but can increase time to arrhythmia termination or cause unnecessary charges

Superior Specificity
PARAD+TM is an enhancement of PARADTM, which has been shown to have the best arrhythmia classification1. PARAD+TM provides superior arrhythmia discrimination (94% specificity). Minimizing inappropriate shocks2.


FVT Stability Analysis

  • No inappropriate ATP
  • No delay in case of VF


Safe and Painless3

  • Antitachycardia pacing is programmable in three VT zones, slow VT, VT, and fast VT for painless therapy
  • Autoswitch ATP: The last successful ATP therapy is applied as a priority
  • Unnecessary charges are avoided when ATP is effective
  • Fast VTs stability is analyzed allowing the selection of ATP or shock therapy

1. “After correction for the clinical prevalence of the simulated supraventricular tachyarrhythmias the specifi city was: ELA medical: 99%; Biotronic: 95%; Guidant: 94%, Medtronic: 93%, St Jude: 92%” Hintringer F et al: Comparison of the specifi city of implantable dual chamber defibrillator detection algorithms. PACE 2004;27:976-982.
2. Unique long cycle search criteria is used to avoid treating AF that is rapidly conducted to the ventricle, and thus limits inappropriate therapies for AF to 0.3% to 0.8%risk per patient. Mletzko R et al:Enhanced Specificity of a Dual Chamber ICD Arrhythmia Detection Algorithm by Rate Stability criteria. PACE 2004;27:1113-1119.
3. ”Empirical ATP is highly effective in treating FVT. It prevents painful shocks without any clinical difference in episode duration, arrhythmic syncope, acceleration, or sudden death while yielding improvement in QoL. The investigators of the PainFREE Rx II trial recommend ATP as the preferred therapy for FVT in most ICD patients.” Mark S. Wathen et al., Reduces Shock Therapies (PainFREE Rx II) Trial Results Implantable Cardioverter-Defibrillators: Pacing Fast Ventricular TachycardiaVersus Shocks for Spontaneous Rapid Ventricular Tachycardia in Patients With Prospective Randomized Multicenter Trial of Empirical Antitachycardia Pacing, Journal of the Amercian heart Association, Circulation 2004;110;2591-2596.
4. Kiès P et al. Cardiac resynchronisation therapy in chronic atrial fibrillation: impact on left atrial size and reversal to sinus rhythm. Heart. 2006 Apr;92(4):490-4.
5. Anselme F, et al.: Prevention of Inappropriate shocks in ICD Recipients: A review of 10000 Tachycardia Episodes. PACE 2007;30: Sup1.

Warning:
This product may not be for sale in your country or your area. For further information on product availability, please contact your local representative

 
Clinical Update